for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

参天製薬株式会社

4536.T

現在値

964.00JPY

変化

-18.00(-1.83%)

出来高

1,979,600

本日のレンジ

960.00

 - 

970.00

52週レンジ

960.00

 - 

1,680.00

∙ 約20分前の相場を表示しています。

適時開示

Santen Pharmaceutical - Bought Back 1,307,300 Own Shares From Sept 1 to 8

TOKYO, Sept 9 (Reuters) - SANTEN PHARMACEUTICAL - BOUGHT BACK 1,307,300 OWN SHARES FROM SEPT 1 TO 8:Further company coverage: [<4536.T>].

Santen Pharmaceutical Co Ltd - Bought Back 3,539,900 Own Shares In August

Sept 1 - :Further company coverage: 4536.T.

Santen Pharmaceutical Co Ltd: Bought Back 547,300 Own Shares Worth 596.4 Million Yen In July

Aug 1 (Reuters) - Santen Pharmaceutical Co Ltd <4536.T>::SANTEN PHARMACEUTICAL CO LTD: BOUGHT BACK 547,300 OWN SHARES WORTH 596.4 MILLION YEN IN JULY.

Santen Pharmaceutical: To Buy Back Up To 3.1% Of Own Shares Worth 15 Billion Yen

May 10 (Reuters) - :SANTEN PHARMACEUTICAL SAYS TO BUY BACK UP TO 3.1% OF OWN SHARES WORTH 15 BILLION YEN ($115 million).Further company coverage: 4536.T.($1 = 130.3600 yen).

Santen Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Cyclosporine Topical Ophthalmic Emulsion, 0.1%

Oct 26 (Reuters) - Santen Pharmaceutical Co Ltd <4536.T>::SANTEN ANNOUNCES U.S. FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION (NDA) FOR CYCLOSPORINE TOPICAL OPHTHALMIC EMULSION, 0.1% FOR THE TREATMENT OF SEVERE VERNAL KERATOCONJUNCTIVITIS IN PATIENTS AGES 4-18.SANTEN INC - FDA HAS SET JUNE 26, 2021 AS PDUFA GOAL DATE FOR CYCLOSPORINE TOPICAL OPHTHALMIC EMULSION.

Santen Pharmaceutical Will Enter The Indian Market This Year - Nikkei

Aug 8 (Reuters) - NIKKEI: :JAPAN'S SANTEN PHARMACEUTICAL WILL ENTER THE INDIAN MARKET THIS YEAR WITH GLAUCOMA AND DRY-EYE MEDICINES - NIKKEI.

Santen Pharmaceutical To Buy Back Up To 2 Percent Of Its Shares Worth 14 Billion Yen Through March 22

Feb 20 (Reuters) - Santen Pharmaceutical Co Ltd <4536.T>::TO BUY BACK UP TO 2 PERCENT OF ITS SHARES WORTH 14 BILLION YEN THROUGH MARCH 22.

PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical

Sept 25(Reuters) - PeptiDream Inc <4587.T>:Says it has entered into a broad-based multi-target discovery and development agreement with Santen Pharmaceutical Co Ltd <<<4536.T>>>.

Aequus Pharmaceuticals enters into agreement with Santen Pharmaceutical's unit

June 13 (Reuters) - Aequus Pharmaceuticals Inc <AQS.V>-:Has entered into an exclusive agreement in Canada with a unit of Santen Pharmaceutical.Under agreement, Aequus and Santen will plan to co-commercialize an undisclosed ophthalmology therapeutic product.Aequus Pharmaceuticals - as per agreement, santen will be responsible for product manufacturing, distribution, co will be responsible for field activities.Net product revenues will be split between aequus and santen over a ten-year term.

Santen Pharmaceutical to retire treasury shares

Santen Pharmaceutical Co Ltd <4536.T>: Says it to retire 8,300,000 shares (2 percent stake) of its common stock on Dec. 29 .Says the total shares outstanding will be 406,005,015 shares after the retirement.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up